Patient P-01699
Therapy response
Improving
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Improving
Discontinuation risk
59%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S04
- Day 80 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 82 GI-04 recommended — GI Support Protocol GI-04
- Day 83 Patient accepted — Started GI-04 in the companion
- Day 91 GI symptom burden −24% vs expected — GI Support Protocol GI-04
- Day 97 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 80.
Primary contributors, last 14 days
- GI instability+10
- Toxicity-7
- Treatment adherence-6
- Nutritional resilience+4
What helped?
- GI Support Protocol GI-04Day 82Result: symptom burden −24%
LIFE OS recommendation
Dietary Support Protocol NP-02
66%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 86% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 51
- Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 48
- Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 53 and rising
- Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑25
- WearableResting HR 85 bpm
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2 · butyrate capacity 47/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 38 ms
- Sleep
- 7.2 h
- Steps
- 7,503
- Resting HR
- 85 bpm
Daily log: GI score 53, nutritional resilience 43, adherence 77.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01795 | 49% | S06 | — | — | 61 |
| P-01371 | 48% | S06 | CR-01 | improved | 63 |
| P-01769 | 47% | S20 | — | — | 60 |
| P-01696 | 43% | S20 | CR-01 | improved | 59 |
| P-01459 | 42% | S02 | — | — | 51 |
| P-01310 | 41% | S01 | — | — | 57 |
| P-01388 | 41% | S17 | CR-01 | improved | 59 |
| P-01442 | 41% | S13 | CR-01 | improved | 61 |
| P-01469 | 41% | S19 | — | — | 58 |
| P-01600 | 41% | S06 | — | — | 51 |
| P-01708 | 41% | S07 | CR-01 | improved | 59 |
| P-01794 | 41% | S09 | — | — | 54 |